Ziółko Ewa, Knopik Jacek, Bucior Jacek, Foltyn Wanda, Jastrzebska-Okoń Krystyna, Tomczyk Andrzej, Kempiński Marcin
Oddział Kliniczny Chorób Wewnetrznych SI. AM, Bytom.
Pol Merkur Lekarski. 2004 Jun;16(96):561-4.
Anxiety accompanies patients at all stages of severe somatic diseases as well in the course of diagnostic procedures. It affects significantly quality of life of these patients and their relations with their physicians. It may also induce or exacerbate wide range of somatic complaints.
Evaluation of usefulness of anxiolytic therapies in patients with diagnosed neoplastic diseases. Comparison of anti-anxiety and antidepressant effects of alprazolam and diazepam in patients treated with systemic chemotherapy.
Final analysis included 45 patients with various malignancies randomly assigned to receive alprazolam 3 x 0.5 mg or diazepam 3 x 2 mg. Anti-anxiety effects of both drugs was evaluated four times during the 21-day follow-up period at one week intervals with help of Clinical Global Impression scale (CGI), Hamilton Anxiety Rating Scale (HARS), Hospital Anxiety and Depression Scale (HADS). Analysis of these questionnaires was performed with Mann-Whitney test and Wilcoxon test.
Statistically significant reduction of anxiety was found in both study groups. Alprazolam was proven to be significantly more effective than diazepam in reduction of anxiety (HARS, HADS) and depressive symptoms accompanying anxiety (HADS). Alprazolam vs. diazepam showed better tolerance by patients.
Alprazolam effectively reduced anxiety in patients suffering from malignant diseases. Alprazolam was found to reduce depressive symptoms in patients with neurotic disorders whereas no effects of this kind were observed for diazepam.
焦虑在严重躯体疾病的各个阶段以及诊断过程中都伴随着患者。它显著影响这些患者的生活质量以及他们与医生的关系。它还可能诱发或加剧各种躯体不适。
评估抗焦虑疗法对已确诊肿瘤疾病患者的有效性。比较阿普唑仑和地西泮在接受全身化疗患者中的抗焦虑和抗抑郁效果。
最终分析纳入45例患有各种恶性肿瘤的患者,他们被随机分配接受3次,每次0.5毫克的阿普唑仑或3次,每次2毫克的地西泮。在为期21天的随访期间,每隔一周使用临床总体印象量表(CGI)、汉密尔顿焦虑评定量表(HARS)、医院焦虑抑郁量表(HADS)对两种药物的抗焦虑效果进行4次评估。使用曼-惠特尼检验和威尔科克森检验对这些问卷进行分析。
两个研究组的焦虑水平均有统计学意义的降低。事实证明,阿普唑仑在减轻焦虑(HARS、HADS)以及伴随焦虑的抑郁症状(HADS)方面比地西泮显著更有效。阿普唑仑与地西泮相比,患者耐受性更好。
阿普唑仑有效减轻了患有恶性疾病患者的焦虑。发现阿普唑仑可减轻神经症患者的抑郁症状,而地西泮未观察到此类效果。